Effects of 3,5,4′-tri-[4-(nitrooxy)butanoyl]oxy resveratrol, a new nitric oxide-releasing derivative of resveratrol, on platelet activation
Pharmacological Reports · 2025
DOI: 10.1007/s43440-024-00691-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Reports, 2025. Verfasst von Giuseppe Guglielmini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Strada Vicinale Via Delle Corse, 06132, …. Hauptthemen laut MEDLINE: Nitric Oxide, Platelet Activation, Stilbenes, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Resveratrol is a polyphenol of red wine that is thought to contribute to the "French paradox" by protecting against atherosclerotic cardiovascular events. It has anti-inflammatory and antioxidant properties and enhances nitric oxide (NO) production. However, in conditions of severe endothelial dysfunction, its cardiovascular protective effects may be limited. Our study aimed to synthesize and characterize a new nitro derivative of resveratrol, trinitroresveratrol (TN-RSV), for its potential nitric oxide-donating and antiplatelet effects. METHODS: 3,5,4'-tri-[4-(nitrooxy)butanoyl]oxy resveratrol (TN-RSV) was synthetized starting from commercial resveratrol (RSV) through the intermediacy of 3,5,4'-tri-(4-bromo-butanoyl)oxy resveratrol. Platelet aggregation was assessed by light transmission aggregometry (LTA) using collagen as agonist. The release of nitric oxide (NO) from TN-RSV or from activated platelets was assessed as the concentration of the NO degradation products (nitrites plus nitrates, NOx) in the supernatant. Platelet adhesion to collagen under flow conditions was assessed using a parallel plate perfusion chamber. Reactive oxygen species (ROS) production from collagen-activated platelets was assessed by flow cytometry using the fluorescent probe H2DCFDA. RESULTS: TN-RSV spontaneously released NO and significantly inhibited collagen-induced platelet aggregation in a dose-dependent manner. This effect was greater than that of resveratrol and it was not affected by the preincubation with L-NAME, a nitric-oxide synthase (NOS) inhibitor, indicating that TN-RSV directly inhibits platelet activation independently of NOS. CONCLUSIONS: Our findings suggest that TN-RSV has potential as an antiplatelet agent and that further research exploring its therapeutic applications for conditions associated with endothelial dysfunction and platelet hyperreactivity is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Strada Vicinale Via Delle Corse, 06132, Perugia, Italy.
- Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
- Division of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Strada Vicinale Via Delle Corse, 06132, Perugia, Italy. paolo.gresele@unipg.it.
Zitieren
APA
Guglielmini, G., Berardi, E., Messina, F., Marcotullio, M. C., & Gresele, P. (2025). Effects of 3,5,4′-tri-[4-(nitrooxy)butanoyl]oxy resveratrol, a new nitric oxide-releasing derivative of resveratrol, on platelet activation. Pharmacological Reports. https://doi.org/10.1007/s43440-024-00691-5
Vancouver
Guglielmini G, Berardi E, Messina F, Marcotullio MC, Gresele P. Effects of 3,5,4′-tri-[4-(nitrooxy)butanoyl]oxy resveratrol, a new nitric oxide-releasing derivative of resveratrol, on platelet activation. Pharmacological Reports. 2025. doi:10.1007/s43440-024-00691-5
BibTeX
@article{Guglielmini2025,
author = {Guglielmini, Giuseppe and Berardi, Emanuela and Messina, Federica and Marcotullio, Maria Carla and Gresele, Paolo},
title = {Effects of 3,5,4′-tri-[4-(nitrooxy)butanoyl]oxy resveratrol, a new nitric oxide-releasing derivative of resveratrol, on platelet activation},
journal = {Pharmacological Reports},
year = {2025},
doi = {10.1007/s43440-024-00691-5}
}
EUVIMED